Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the

NurExone Announces Additional Securities for Debt Settlemen Read More

Under the Letter of Intent, NurExone will explore collaborations with denovoMATRIX to use its advanced screenMATRIX platform to develop specialized coatings for NurExone’s cell carriers for exosome production in order to optimize the manufacturing processes of the non-invasive NurExone’s ExoTherapy. The primary aim of the collaboration is to develop a

Calgary, Alberta–(Newsfile Corp. – September 1, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed

Calgary, Alberta–(Newsfile Corp. – August 25, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the quarter ended June 30, 2022. 

https://www.newsfilecorp.com/release/133194/James-Richardson-the-Former-CEO-of-EnerSpar-Updates-Shareholders-After-the-Completion-of-RTO-with-NurExone-Biologic

Newsfile Corp. July 19, 2022·5 min read Calgary, Alberta–(Newsfile Corp. – July 19, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, announced the signing of a Material

https://finance.yahoo.com/news/nurexone-provides-corporate-120000076.html

“ExoTherapy”, NurExone’s proprietary Exosome siRNA loaded product, is being developed to recover functionality in patients with traumatic spinal cord injuries read more

Bnei-Brak, Israel–(Newsfile Corp. – June 22, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (“NurExone” or the “Company“) is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it will commence trading on the TSX Venture Exchange (the “TSXV“) under